ArticleInternational journal of hematology2014

Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression.

Yan Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.